Strategic Partnership Ametris is actively pursuing and securing strategic collaborations, evidenced by recent partnerships with Kayentis and involvement in DECODE Obesity with major biopharma players. This signals openness to co-develop integrated digital health solutions, creating cross-sell and co-sell opportunities for analytics, wearable tech, and eCOA offerings.

Acquisition Momentum News of Signant Health announcing an agreement to acquire Ametris indicates the market value of Ametris’ technology and platform. This presents an upsell pathway for enterprise clients seeking robust digital health platforms, as well as potential integration or migration opportunities with Signant’s ecosystem.

Wearable and eCOA Expertise Ametris concentrates on integrated wearable technology and electronic clinical outcome assessments, offering a strong foothold for CROs and pharma companies aiming to improve device adherence and data quality in decentralized trials.

Regulatory‑Aligned Digital The end-to-end DHT platform emphasizes regulatory-aligned analytics across study design to submission, aligning with sponsors’ needs for compliant real-world data. This supports solution selling around regulatory readiness, data integrity, and faster time-to-submission.

Growth through DECODE Active participation in DECODE obesity and neuromuscular initiatives with top pharma partners suggests opportunities to cross-sell digital measurement frameworks, functional capacity metrics, and evidence generation capabilities to additional therapeutic areas and trials.